Safety and efficacy of sintilimab versus pembrolizumab in the treatment of advanced or recurrent pediatric malignancies: a real-world study in China

Safety and efficacy of sintilimab versus pembrolizumab in the treatment of advanced or recurrent pediatric malignancies: a real-world study in China

BackgroundProgrammed death receptor 1 (PD-1) inhibitors have shown durable response and mild adverse events in adult malignancies. However, study on PD-1 inhibitors in pediatric patients remains limited, and a direct comparison of distinct PD-1 inhibitors in pediatric tumors is lacking.MethodsWe con...

Full description

Saved in:
Bibliographic Details
Main Authors: Lei Mao, Mengzhen Li, Linnan Wu, Juan Wang, Yi Que, Feifei Sun, Junting Huang, Suying Lu, Zijun Zhen, Jia Zhu, Mengjia Song, Yizhuo Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-06-01
Series:Frontiers in Immunology
Subjects:
pediatric malignancies
PD-1 inhibitors
sintilimab
pembrolizumab
safety
efficacy
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1608844/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2025.1608844/full

Similar Items